These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38488975)

  • 1. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Warren RB; McInnes IB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; Mease PJ
    Rheumatol Ther; 2024 Jun; 11(3):829-839. PubMed ID: 38488975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Jun; 11(3):817-828. PubMed ID: 38446397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Oct; 11(5):1403-1412. PubMed ID: 39120849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Oct; 11(5):1413-1423. PubMed ID: 39120848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ; Merola JF; Tanaka Y; Gossec L; McInnes IB; Ritchlin CT; Landewé RBM; Asahina A; Ink B; Heinrichs A; Bajracharya R; Shende V; Coarse J; Coates LC
    Rheumatol Ther; 2024 Oct; 11(5):1363-1382. PubMed ID: 39215949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
    Ogdie A; Merola JF; Mease PJ; Ritchlin CT; Scher JU; Lafferty KP; Chan D; Chakravarty SD; Langholff W; Wang Y; Choi O; Krol Y; Gottlieb AB
    BMC Rheumatol; 2024 May; 8(1):20. PubMed ID: 38773563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.
    Gossec L; Orbai AM; de Wit M; Coates LC; Ogdie A; Ink B; Coarse J; Lambert J; Taieb V; Gladman DD
    Rheumatology (Oxford); 2024 Sep; 63(9):2399-2410. PubMed ID: 38754125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
    Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
    Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
    Ritchlin CT; Helliwell PS; Boehncke WH; Soriano ER; Hsia EC; Kollmeier AP; Chakravarty SD; Zazzetti F; Subramanian RA; Xu XL; Zuraw QC; Sheng S; Jiang Y; Agarwal P; Zhou B; Zhuang Y; Shawi M; Karyekar CS; Deodhar A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33568556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.
    McInnes IB; Mease PJ; Tanaka Y; Gossec L; Husni ME; Kristensen LE; Warren RB; Ink B; Bajracharya R; Coarse J; Gottlieb AB
    ACR Open Rheumatol; 2024 Nov; 6(11):720-731. PubMed ID: 39077886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
    Ritchlin CT; Deodhar A; Boehncke WH; Soriano ER; Kollmeier AP; Xu XL; Zazzetti F; Shawi M; Jiang Y; Sheng S; Helliwell PS
    ACR Open Rheumatol; 2023 Mar; 5(3):149-164. PubMed ID: 36762512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials.
    Thilakarathne P; Schubert A; Peterson S; Noel W; Patel BP; Hassan F
    Rheumatol Ther; 2024 Apr; 11(2):457-474. PubMed ID: 38416392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
    Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden.
    Sigurdardottir V; Engstrom A; Berling P; Olofsson T; Oldsberg L; Sadler S; Parra-Padilla D; Melis L; Willems D
    J Med Econ; 2023; 26(1):1190-1200. PubMed ID: 37712618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials.
    Mease P; Korotaeva T; Shesternya P; Kokhan M; Rukavitsyn A; Vasilchenkov D; Sharaf M; Lavie F; Deodhar A
    Rheumatol Ther; 2024 Dec; 11(6):1551-1567. PubMed ID: 39320583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
    Coates LC; Gossec L; Theander E; Bergmans P; Neuhold M; Karyekar CS; Shawi M; Noël W; Schett G; McInnes IB
    Ann Rheum Dis; 2022 Mar; 81(3):359-369. PubMed ID: 34819273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
    Clin Rheumatol; 2024 Aug; 43(8):2551-2563. PubMed ID: 38844682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
    Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
    Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.
    Rahman P; Boehncke WH; Mease PJ; Gottlieb AB; McInnes IB; Shawi M; Wang Y; Sheng S; Kollmeier AP; Theander E; Yu J; Leibowitz E; Marrache AM; Coates LC
    J Rheumatol; 2023 Jun; 50(6):769-780. PubMed ID: 36642439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.